saralasin - CISMeF

Preferred Label : saralasin;

MeSH definition : An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.;

MeSH synonym : (sar1,val5,ala8)angiotensin ii; 1-sarcosine-8-alanine angiotensin ii; 1-sar-8-ala angiotensin ii; 1 sar 8 ala angiotensin ii; angiotensin ii, 1-sar-8-ala; angiotensin ii, sar(1)-ala(8)-; (sar(1),ala(8))angii; angiotensin ii, sarcosyl(1)-alanine(8)-; 1 sarcosine 8 alanine angiotensin ii; angiotensin ii, 1-sarcosine-8-alanine; sar-arg-val-tyr-val-his-pro-ala;

CISMeF synonym : sar arg val tyr val his pro ala; 1-sar-8-ala-angiotensin ii; P-113 acetate; acetate, hydrated saralasin;

CISMeF acronym : P-113;

MeSH hyponym : saralasin acetate, anhydrous; saralasin acetate; Saralasin Acetate, Hydrated; Hydrated Saralasin Acetate; Anhydrous Saralasin Acetate;

MeSH CAS label : angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-;

MeSH Related Number : saralasin acetate, anhydrous; 39698-78-7 (acetate, hydrated); 54194-01-3 (acetate, anhydrous); 34273-10-4 (Saralasin); FO21Z580M4; U603K01682;

Registry Number MeSH : 34273-10-4;

Related CAS MeSH : 54194-01-3 (Saralasin acetate, anhydrous);

Wikipedia link : https://en.wikipedia.org/wiki/Saralasin;

Is substance : O;

UNII : H2AFV2HE66;

Details

Origin ID

D012504;

UMLS CUI

C0036193;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Saralasin [ICD-11 Extension code]
- Saralasin [ICHI extension code]
- Saralasin [SMS substance]
- Saralasin [NCIt concept]
Pharmacological action(s)
- angiotensin II type 1 receptor blockers [MeSH Descriptor]
- angiotensin-converting enzyme inhibitors [MeSH Descriptor]
- antihypertensive agents [MeSH Descriptor]
Record concept(s)
- saralasin [MeSH concept]
- saralasin acetate [MeSH concept]
- saralasin acetate, anhydrous [MeSH concept]
Related MeSH Supplementary Concept(s)
- angiotensin II, 1-Sar-5-Ile-8-Ala- [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Saralasin [ICD-11 Extension code]
- Saralasin [NCIt concept]
Validated automatic mappings to BTNT
- Saralasin acetate [SMS substance]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients